Dyne Therapeutics Inc

DYN

13.240USD

-0.240-1.78%

Close 09/04, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

206 / 689

Overall Ranking

325 / 4737

Industry

Pharmaceuticals & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 17 analysts

Buy

Current Rating

36.133

Target Price

+167.65%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 88.83.

Undervalued

The company’s latest PE is -3.47, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 126.04M shares, increasing 4.85% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 7.64M shares of this stock.

There is no financial score for this company; the Pharmaceuticals & Medical Research industry's average is 6.80.

Score

Industry at a Glance

Previous score

0.00

Change

0



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is -3.51, which is -27.56% below the recent high of -2.54 and 7.72% above the recent low of -3.24.

Score

Industry at a Glance

Previous score

1.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 206/689

No Data

The company’s current earnings forecast score is 8.35, which is higher than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for Dyne Therapeutics Inc is 38.00, with a high of 50.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.47

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 9.49, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 15.21 and the support level at 10.82, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.10

Change

0.14

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-03

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 90.68%, representing a quarter-over-quarter decrease of 18.25%. The largest institutional shareholder is The Vanguard, holding a total of 7.64M shares, representing 5.37% of shares outstanding, with 18.39% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

10.35M

+40.30%

RA Capital Management, LP

9.71M

+52.24%

Atlas Venture

9.13M

+13.86%

The Vanguard Group, Inc.

Star Investors

7.39M

+10.43%

BlackRock Institutional Trust Company, N.A.

6.26M

+1.56%

Forbion Capital Partners

5.46M

--

Fidelity Management & Research Company LLC

5.19M

-31.52%

Invus Public Equities Advisors, LLC

2.72M

+101.71%

TCG Crossover Management, LLC

2.65M

--

State Street Global Advisors (US)

3.61M

-2.90%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.01, which is lower than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 1.09. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Dyne Therapeutics Inc

DYN

5.02 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

7.54 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Stoke Therapeutics Inc

STOK

7.50 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

7.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.43 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.